PET surveillance of patients with Ewing sarcomas of the trunk: Must the lower legs be included?

NuklearMedizin

Volumn 49, Issue 5, 2010, Pages 183-186

  Vrachimis, Alexis ^a   Dirksen, U ^a   Wessling J ^a   Wenning, C ^a,b   Stegger, L ^a   Franzius, C ^c   Juergens, H ^a   Schober, O ^a,b   Weckesser, M ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c MR und PET/CT Zentrum Bremen Mitte   (Germany)

Author keywords

Ewing sarcoma; FDG PET; Legs; Surveillance; Trunk

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE;

ADOLESCENT; ADULT; ARTICLE; CANCER PATIENT; CANCER REGRESSION; CHILD; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; EWING SARCOMA; FEMALE; FOLLOW UP; HUMAN; LOWER LEG; MALE; METASTASIS; NEUROECTODERM TUMOR; PATIENT POSITIONING; PATIENT REFERRAL; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; TRUNK; TUMOR LOCALIZATION; WHOLE BODY SCINTISCANNING;

ADOLESCENT; ADULT; CHILD; COMBINED MODALITY THERAPY; FEMALE; FIBROMA; FLUORODEOXYGLUCOSE F18; HUMANS; LEG; MALE; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; SARCOMA, EWING'S;

EID: 77957878959     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/nukmed-03131004     Document Type: Article

References (21)

1. Fruth C, Amthauer H, Denecke T et al. Impact of whole body MRI and FDG-PET on staging and assessment of therapy response in a patient with Ewing sarcoma. Pediatr Blood Cancer 2006; 47: 607-611. (Pubitemid 44360062)
2. Paulussen M, Ahrens S, Dunst J et al. Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol 2001; 19: 1818-1829.
3. Grier HE. The Ewing family of tumors: Ewing's sarcoma and primitive neuroectodermal tumors. Pediatr Clin North Am 1997; 44: 991-1004. (Pubitemid 27368675)
4. Grier HE, Krailo MD, Tarbell NJ et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003; 348: 694-701.
5. Cotterill SJ, Ahrens S, Paulussen M et al. Prognostic factors in Ewing's tumor of bone: Analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000; 18: 3108-3114.
6. Paulussen M, Ahrens S, Craft AW et al. Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. J Clin Oncol 1998; 16: 3044-3052.
7. Paulussen M, Ahrens S, Burdach S et al. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol 1998; 9: 275-281. (Pubitemid 28186797)
8. Haeusler J, Ranft A, Boelling T et al. The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES). Cancer 2010; 15: 443-450.
9. Györke T, Zajic T, Lange A et al. Impact of FDG PET for staging of Ewing sarcomas and primitive neuroectodermal tumours. Nucl Med Commun. 2006; 27: 17-24. (Pubitemid 44391835)
10. Völker T, Denecke T, Steffen I et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol 2007; 25: 5435-5441.
11. Gerth HU, Juergens KU, Dirksen U et al. Significant benefit of multimodal imaging: PET/CT compared with PET alone in staging and follow-up of patients with Ewing tumors. J Nucl Med 2007; 48: 1932-1939. (Pubitemid 350237602)
12. Jones DN, McCowage GB, Sostman HD et al. Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. J Nucl Med 1996; 37: 1438-1444.
13. 18F-fluorodeoxy- D-glucose positron emission tomography. Cancer 2002; 94: 3277-3284;
14. Cancer 2003; 97: 3130.
15. 18F- Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol 2005; 23: 8828-8834.
16. Franzius C, Sciuk J, Brinkschmidt C et al. Evaluation of chemotherapy response in primary bone tumors with 18F-FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin Nucl Med 2000; 25: 874-881.
17. 18F-FDG PET and PET-CT imaging in paediatric oncology. European Association of Nuclear Medicine. Eur J Nucl Med Mol Imaging 2008; 35: 1581-1588; 2140.
18. Franzius C, Daldrup-Link HE, Sciuk J et al. FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol 2001; 12: 479-486.
19. Iagaru A, Chawla S, Menendez L, Conti PS. 18F-FDG PET and PET/CT for detection of pulmonary metastases from musculoskeletal sarcomas. Nucl Med Commun 2006; 27: 795-802. (Pubitemid 44401248)
20. Löffler M, Weckesser M, Franzius C et al. Malignant melanoma and 18F-FDG-PET: Should the whole body scan include the legs? Nuklearmedizin 2003; 42: 167-172.
21. Lassmann M, Biassoni L, Monsieurs M et al. EANM Dosimetry and Paediatrics Committees. The new EANM paediatric dosage card. Eur J Nucl Med Mol Imaging 2007; 34: 796-798.